Shattuck Labs, Inc. Expected to Earn FY2025 Earnings of ($2.00) Per Share (NASDAQ:STTK)

Shattuck Labs, Inc. (NASDAQ:STTK) – Analysts at HC Wainwright cut their FY2025 EPS estimates for Shattuck Labs in a note issued to investors on Wednesday, April 10th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($2.00) per share for the year, down from their prior estimate of ($1.95). HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.85) per share.

Separately, Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of Shattuck Labs in a report on Tuesday, April 9th.

Shattuck Labs Price Performance

Shares of STTK opened at $8.98 on Monday. Shattuck Labs has a one year low of $1.33 and a one year high of $11.11. The company has a 50-day simple moving average of $9.12 and a two-hundred day simple moving average of $6.23. The firm has a market capitalization of $426.28 million, a PE ratio of -4.38 and a beta of 2.11.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, February 29th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.10. The company had revenue of $0.71 million during the quarter, compared to analyst estimates of $0.50 million. Shattuck Labs had a negative net margin of 5,268.44% and a negative return on equity of 63.08%.

Hedge Funds Weigh In On Shattuck Labs

Institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in shares of Shattuck Labs during the first quarter valued at approximately $30,000. UBS Group AG increased its stake in shares of Shattuck Labs by 62.3% during the first quarter. UBS Group AG now owns 10,978 shares of the company’s stock valued at $32,000 after purchasing an additional 4,214 shares in the last quarter. Balyasny Asset Management LLC bought a new position in shares of Shattuck Labs during the third quarter valued at approximately $35,000. Acadian Asset Management LLC bought a new position in shares of Shattuck Labs during the first quarter valued at approximately $37,000. Finally, Jane Street Group LLC bought a new position in shares of Shattuck Labs during the first quarter valued at approximately $58,000. Institutional investors own 58.74% of the company’s stock.

Insiders Place Their Bets

In other Shattuck Labs news, insider Stephen Stout sold 16,004 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total transaction of $168,522.12. Following the completion of the transaction, the insider now owns 74,437 shares of the company’s stock, valued at $783,821.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.46% of the stock is currently owned by company insiders.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.